Literature DB >> 26516547

Splice variation of the mu-opioid receptor and its effect on the action of opioids.

Sophy K Gretton1, Joanne Droney2.   

Abstract

An individual's response to opioids is influenced by a complex combination of genetic, molecular and phenotypic factors.Intra- and inter-individual variations in response to mu opioids have led to the suggestion that mu-opioid receptor subtypes exist.Scientists have now proven that mu-opioid receptor subtypes exist and that they occur through a mechanism promoting protein diversity, called alternative splicing.The ability of mu opioids to differentially activate splice variants may explain some of the clinical differences observed between mu opioids.This article examines how differential activation of splice variants by mu opioids occurs through alternative mu-opioid receptor binding, through differential receptor activation, and as a result of the distinct distribution of variants located regionally and at the cellular level.

Keywords:  OPRM1; Pain; genetic; mu opioids; mu-opioid receptor; opioid; pharmacogenetic; splice variants; splice variation

Year:  2014        PMID: 26516547      PMCID: PMC4616723          DOI: 10.1177/2049463714547115

Source DB:  PubMed          Journal:  Br J Pain        ISSN: 2049-4637


  53 in total

1.  Isolation of an endogenous compound from the brain with pharmacological properties similar to morphine.

Authors:  J Hughes
Journal:  Brain Res       Date:  1975-05-02       Impact factor: 3.252

Review 2.  Is target opioid therapy within sight?

Authors:  G Finco; M Pintor; D Sanna; G Orrù; M Musu; F De Conno; A Marchi; F Paribello; E D'Aloja
Journal:  Minerva Anestesiol       Date:  2012-02-06       Impact factor: 3.051

3.  The impact of microRNAs and alternative splicing in pharmacogenomics.

Authors:  F Passetti; C G Ferreira; F F Costa
Journal:  Pharmacogenomics J       Date:  2009-02       Impact factor: 3.550

4.  Cloning and expression of an isoform of the rat mu opioid receptor (rMOR1B) which differs in agonist induced desensitization from rMOR1.

Authors:  A Zimprich; T Simon; V Höllt
Journal:  FEBS Lett       Date:  1995-02-13       Impact factor: 4.124

Review 5.  Preclinical pharmacology and opioid combinations.

Authors:  Gavril W Pasternak
Journal:  Pain Med       Date:  2012-03       Impact factor: 3.750

6.  Expression of two variants of the human mu opioid receptor mRNA in SK-N-SH cells and human brain.

Authors:  L A Bare; E Mansson; D Yang
Journal:  FEBS Lett       Date:  1994-11-07       Impact factor: 4.124

7.  Differential expression and HIV-1 regulation of μ-opioid receptor splice variants across human central nervous system cell types.

Authors:  Seth M Dever; Ruqiang Xu; Sylvia Fitting; Pamela E Knapp; Kurt F Hauser
Journal:  J Neurovirol       Date:  2012-04-20       Impact factor: 2.643

8.  mu opiate receptor: cDNA cloning and expression.

Authors:  J B Wang; Y Imai; C M Eppler; P Gregor; C E Spivak; G R Uhl
Journal:  Proc Natl Acad Sci U S A       Date:  1993-11-01       Impact factor: 11.205

9.  Stereospecific binding of the potent narcotic analgesic (3H) Etorphine to rat-brain homogenate.

Authors:  E J Simon; J M Hiller; I Edelman
Journal:  Proc Natl Acad Sci U S A       Date:  1973-07       Impact factor: 11.205

10.  Separation of morphine analgesia from physical dependence.

Authors:  G S Ling; J M MacLeod; S Lee; S H Lockhart; G W Pasternak
Journal:  Science       Date:  1984-10-26       Impact factor: 47.728

View more
  2 in total

1.  Cancer pain for the 21st century: stepping off the ladder, stepping up to new challenges.

Authors:  Sam H Ahmedzai
Journal:  Br J Pain       Date:  2014-11

2.  European Pain Federation position paper on appropriate opioid use in chronic pain management.

Authors:  T O'Brien; L L Christrup; A M Drewes; M T Fallon; H G Kress; H J McQuay; G Mikus; B J Morlion; J Perez-Cajaraville; E Pogatzki-Zahn; G Varrassi; J C D Wells
Journal:  Eur J Pain       Date:  2017-01       Impact factor: 3.931

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.